Varian’s Halcyon got nod from Taiwan, China FDA

Varian announced its Halcyon system has received Taiwan, China FDA approval, which allows the company to market this new cancer treatment system in China's Taiwan, China Region.

This approval further expands the global availability of Halcyon and high-quality, cost-effective cancer treatments.

As an advanced cancer treatment system with a human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training, and automate treatment.

It simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT).

It is well suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head & neck, and many other forms of cancer.

Halcyon has already received FDA 510(k) clearance in the US, CE mark in Europe, Shonin approval in Japan and ANVISA registration in Brazil since its launch in May 2017.

First treatments have shown Halcyon's human-centered and user-friendly design can enhance patient comfort and increase the treatment efficiency.

With the streamlined workflow, Halcyon needs only nine steps from the start to the end of treatment as compared to more than 30 steps with older technologies.